- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Malaria Treatment Market is expected to reach US$ 24,487.73 million by 2030
Nov 02, 2023
Takeda’s $1.7B AI Drug Discovery Deal with Iambic Signals Shift
Feb 10, 2026
Novartis AG to acquire The Medicines Company
Nov 25, 2019
Genentech’s Fenebrutinib Shows Breakthrough MS Results
Feb 16, 2026
CIN and HR-HPV Treatment Market is expected to reach US$ 17,164.61 million by 2028
May 10, 2023
Tiamulin Market Trends, Strong Application Scope, Key Players, Growth Overview and Forecast by 2027
Mar 23, 2021
Infectious Disease Therapeutics Market is expected to reach US$ 1,67,883.93 million by 2030
Jan 25, 2024
Follow us on
